Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily R Hankosky

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 17, 2023
Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009-2020Emily R Hankosky, David Schapiro, Karli B Gunn, et al.
Clinical Therapeutics|June 6, 2025
Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United StatesTheresa Hunter Gibble, Emily R Hankosky, Alexandra Meeks, et al.
Diabetes, Obesity & Metabolism|February 25, 2025
Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity databaseEmily R Hankosky, Chanadda Chinthammit, Alexandra Meeks, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2017
Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [<sup>3</sup>H]dopamine uptake at the vesicular monoamine transporter-2Emily R Hankosky, Shyam R Joolakanti, Justin R Nickell, et al.
Diabetes, Obesity & Metabolism|September 29, 2025
Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trialEmily R Hankosky, Jeremie Lebrec, Clare J Lee, et al.
Current Medical Research and Opinion|May 4, 2023
Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learningEmily R Hankosky, Michelle L Katz, Ludi Fan, et al.
Diabetes, Obesity & Metabolism|March 14, 2025
Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® databaseTheresa Hunter Gibble, Chanadda Chinthammit, Jennifer M Ward, et al.
Diabetes, Obesity & Metabolism|May 5, 2025
Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparisonEmily R Hankosky, Xuanyao He, Raleigh Malik, et al.
Diabetes, Obesity & Metabolism|September 13, 2023
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trialEmily R Hankosky, Hui Wang, Lisa M Neff, et al.
Neurobiology of Aging|March 15, 2016
Beta-hydroxy-beta-methylbutyrate ameliorates aging effects in the dendritic tree of pyramidal neurons in the medial prefrontal cortex of both male and female ratsDaniel G Kougias, Suzanne O Nolan, Wendy A Koss, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 17, 2023
Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009-2020Emily R Hankosky, David Schapiro, Karli B Gunn, et al.
Clinical Therapeutics|June 6, 2025
Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United StatesTheresa Hunter Gibble, Emily R Hankosky, Alexandra Meeks, et al.
Diabetes, Obesity & Metabolism|February 25, 2025
Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity databaseEmily R Hankosky, Chanadda Chinthammit, Alexandra Meeks, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2017
Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [<sup>3</sup>H]dopamine uptake at the vesicular monoamine transporter-2Emily R Hankosky, Shyam R Joolakanti, Justin R Nickell, et al.
Diabetes, Obesity & Metabolism|September 29, 2025
Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trialEmily R Hankosky, Jeremie Lebrec, Clare J Lee, et al.
Current Medical Research and Opinion|May 4, 2023
Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learningEmily R Hankosky, Michelle L Katz, Ludi Fan, et al.
Diabetes, Obesity & Metabolism|March 14, 2025
Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® databaseTheresa Hunter Gibble, Chanadda Chinthammit, Jennifer M Ward, et al.
Diabetes, Obesity & Metabolism|May 5, 2025
Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparisonEmily R Hankosky, Xuanyao He, Raleigh Malik, et al.
Diabetes, Obesity & Metabolism|September 13, 2023
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trialEmily R Hankosky, Hui Wang, Lisa M Neff, et al.
Neurobiology of Aging|March 15, 2016
Beta-hydroxy-beta-methylbutyrate ameliorates aging effects in the dendritic tree of pyramidal neurons in the medial prefrontal cortex of both male and female ratsDaniel G Kougias, Suzanne O Nolan, Wendy A Koss, et al.
Pageof 4